Pregnancy in patients suffering from systemic lupus erythematosus (SLE) can be complicated by a range of factors affecting both the mother and the fetus, and women with the disease were often advised against becoming pregnant. A research review from Yokohama City University Medical Center researchers, however, shows that optimal monitoring and treatment can improve…
Aurinia Pharmaceuticals will host a lupus nephritis expert breakfast on Thursday, Aug. 4, from 8:00 a.m. to 9:30 a.m. in New York City, to discuss the results of its latest clinical trial in treating lupus nephritis. Other topics at the breakfast, intended for investors, sales analysts, and business development professionals, include current lupus treatments, disease…
Sengenics announced five new applications for its patented Immunome Protein Array platform, which has been used in recent studies to discover autoantibody biomarkers for many diseases including lupus. The news came during the Immunomics & Proteomics Symposium held July 25-29, in Brunei and Singapore. Important presenters include world leaders in proteomics including Sengenics’ Chief Scientific Advisor…
Researchers have discovered a potential new noninvasive measurement for the management of lupus nephritis in pediatric and young adult patients that may help not only keep track of disease progression but also monitor therapeutic responses. The study, “Development of a Novel Renal Activity Index of Lupus Nephritis…
Researchers at have identified an RNA molecule, known as a long noncoding RNA, that is responsible for controlling innate immune processes by making sure inflammatory genes in macrophages are switched off until needed. The study, “A Long Noncoding RNA lincRNA-EPS Acts as a Transcriptional Brake to Restrain…
Recent findings may help provide a new diagnostic indicator for the clinical detection of systemic lupus erythematosus (SLE) in previously undiagnosed patients. The study, “Evaluation of PBMC Distribution and TLR9 Expression in Patients with Systemic Lupus Erythematosus,” published in the Iranian Journal of Allergy, Asthma, and Immunology, revealed that specific…
Autoantibodies that naturally occur in the body of a population of patients with an ultra-rare type of autoimmune disorder called autoimmune polyendocrine syndrome type 1 (APS1 or APECED), could help fight a variety of human diseases including lupus.
Kadmon announced the publication of data from preclinical studies supporting its oral drug candidate, KD025, a small molecule ROCK2 inhibitor, as a potential treatment for autoimmune diseases such as systemic lupus erythematosus (SLE). The data indicated that KD025 worked to inhibit the rho-associated coiled-coil kinase 2 signaling pathway (ROCK2), reducing the development and function…
The Office of Minority Health has awarded the American College of Rheumatology’s (ACR) The Lupus Initiative (TLI) a one-year $335,000 grant to continue to expand its national education program by developing an expert-informed model specifically focused on improving health outcomes in lupus patients. “This model is the first of its kind to…
Novato-based Mount Tam Biotechnologies announced the U.S. Patent and Trademark Office has issued a key patent for the company’s lead systemic lupus erythematous (SLE) drug candidate, TAM-01, an innovative small-molecule modulator of the mTOR pathway that plays an important role in regulating the cell cycle. The patent, owned by The Buck Institute…